Takeda Pharmaceutical Co Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on July 2, 2024, reports the results of the 148th Ordinary General Meeting of Shareholders held on June 26, 2024. The filing is a compliance report under the Financial Instruments and Exchange Act regarding shareholder voting outcomes.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to corporate governance compensation:
- Director Bonuses: A total of 500 million yen approved for payment to two specific directors (excluding those residing outside Japan and external directors).
- Dividend: A year-end dividend of 94 yen per share of common stock was approved.
Material Changes and Voting Results
All four proposals presented at the meeting were approved. Key voting statistics include:
- First Proposal (Dividend): Approved with 97.67% of voting rights (11,441,358 for vs. 217,938 against).
- Second Proposal (Election of 10 Directors): All candidates elected. Approval rates ranged from 76.22% (Christophe Weber) to 97.48% (Miki Tsusaka).
- Third Proposal (Election of 4 Audit Committee Directors): All candidates elected. Approval rates ranged from 96.88% to 97.45%.
- Fourth Proposal (Director Bonuses): Approved with 73.63% of voting rights (8,625,102 for vs. 3,017,329 against).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or discussion of contingencies. It is strictly a record of shareholder resolutions.
Investor Verification Checklist
- Verify the final dividend payment date and record date for the approved 94 yen per share dividend.
- Confirm the tenure and specific roles of the newly elected directors, particularly Christophe Weber who received the lowest approval rate (76.22%).
- Review the company's annual report (Form 20-F) for comprehensive financial metrics not included in this filing.